Cáncer de Ovario

Estado: Reclutando

A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, versus Investigator’s Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.

Para inscribirte contáctate a: [email protected]

Principales Criterios de Inclusión:

  • Female participants with histologically-confirmed diagnosis of HGS ovarian, primary peritoneal, or fallopian tube cancer.
    Platinum-resistant disease, defined as:
  • For participants who had only 1 line of platinum-based therapy: progression between > 1 month and ≤ 6 months after the last dose of platinum-based therapy of at least 4 cycles.
  • For participants who had 2 or 3 lines of platinum-based therapy: progression ≤ 6 months after the last dose of platinum-based therapy.
  • Participants have received at least 1 but no more than 3 prior lines of systemic therapy and for whom single-agent therapy is appropriate as the next line of therapy. Participants may have been treated with up to 1 line of therapy subsequent to determination of platinum-resistance.
  • Disease progression per RECIST v1.1 (by investigator assessment) of at least 1 measurable lesion on or after the most recent therapy.
  • Either formalin-fixed, paraffin-embedded (FFPE) tissue (up to 5 years old) or newly-obtained biopsies must be available for FRα assessment prior to randomization.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.»
Ciudades con sitios abiertos a enrolamiento:
Viña del Mar
  • Centro de Investigaciones Clinicas Viña del Mar
  • Bradford Hill
  • Oncovida
  • Clínica Alemana de Temuco

Consulta la Base de Datos
del Buscador de Ensayos Clínicos CIF

Si deseas conocer los datos de los Ensayos Clínicos en desarrollo, accede a nuestra base de datos que tenemos disponible aquí, con información actualizada trimestralmente.

Encuentra tu
ensayo clínico

Elige tu área de interés, patología o región, y accede a tu ensayo clínico.

Buscar ensayos >